the aid library

LIST OPTIONS

Filter

419

Sort by:

Direction:

Download (398)

View PDF (2699)

Community-based care of Ebola virus disease in west Africa

Sharon Salmon, Mary-Louise McLaws, Dale Fisher (2015)

www.thelancet.com/infection Vol 15 February 2015

Download (87)

View PDF (1100)

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV

D. Ford; R. Turner; A. Turkova; et al. JAIDS Journal of Acquired Immune Deficiency Syndromes; Ovid (2018) C2

Supplement Article www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018

Download (1151)

View PDF (816)

Severe Acute Malnutrition Update: Current WHO Guidelines and the WHO Essential Medicine List for Children

Williams, Phoebe CM.; Berkley, James A. (2016) C1

This document was prepared in response to a need to review and potentially update the current recommendations for the antibiotic treatment of both inpatient and outpatient management of severe acute malnutrition (SAM). The current recommendations (Table 1) are based on guidelines published in 2013 i... more

Download (715)

View PDF (1236)

Guidelines for the production, control and regulation of snake antivenom immunoglobulins

World Health Organization (WHO) (2017) C_WHO

Replacement of Annex 2 of WHO Technical Report Series, No. 964... more

Download (1261)

View PDF (3331)

MDR-TB Weight-Based Dosing Chart for Children

Sentinel Project (2013) C1

Therapy for MDR-TB is extremely long, complex and burdensome to both patients and health care systems. A single diagnosis can require two years of treatment, or longer. When treating children, there are significant additional barriers treating children with MDR-TB. There is limited data on the pharm... more

Download (1831)

View PDF (1943)

Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines

Malgosia Grzemska, Elizabeth Mathai World Health Organization WHO (2013)

Download (1385)

View PDF (942)

Zambia: GENERAL GUIDELINES FOR SUBMITTING APPLICATIONS FOR REGISTRATION OF A MEDICINE

Zambia Medicines Regulatory Authority (ZAMRA) (2016) C2

First Edition

Download (85)

View PDF (113)

Tripartite meeting held between the PMDA, EMA, and FDA in Kyoto, Japan to discuss convergence on approaches for the evaluation of antibacterial drugs

European Medicines Agency (2017) C2

Meeting summary

Download (113)

View PDF (375)

Guidelines for the use of antimicrobials in the South African pig industry

Pig Veterinary Society of the South African Veterinary Association (2016) C2

Antimicrobial resistance(AMR) poses a serious threat to human, animal and environmental health. Implementing ethical practice guidelines on how to use antimicrobials effectively and responsibly within the pig industry will contribute in reducing and preventing antimicro... more

Download (121)

View PDF (125)

COVID-19: Chloroquine and hydroxychloroquine research

World Health Organization WHO (2020) C_WHO

This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing clinical tri... more

Download (112)

View PDF (148)

Considerations for introducing new antiretroviral drug formulations for children

World Health Organization WHO (2020) CC

Policy brief. July 2020

Download (118)

View PDF (122)

AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper

World Health Organization WHO, SAGE (2021) C_WHO

10 February 2021. Draft

Download (188)

View PDF (265)

Практический справочник ВОЗ по туберкулезу. Модуль 4. Лечение. Лечение лекарственно-устойчивого туберкулеза

World Health Organization WHO (2021) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (145)

View PDF (208)

Key technical issues of herbal medicines with reference to interaction with other medicines

World Health Organization WHO (2020) C_WHO

Download (94)

View PDF (793)

Pharmacy Courses

Future Learn (2022) CC

Explore best practise in pharmacy, and learn how to start a career as a pharmacist, with these online pharmacy courses from FutureLearn.

Download (95)

View PDF (271)

Full prescribing information Fexinidazole tablets, for oral use

Drugs for Neglected Diseases initiative DNDi (2021) C1

Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati... more

Download (72)

View PDF (83)

Acute schistosomiasis, a diagnostic and therapeutic challenge

Jauréguiberry S., Paris L., Caumes E. (2010) C2

Clin Microbiol Infect 2010; 16: 225–231 Abstract In non-endemic countries, acute (invasive) schistosomiasis (AS) is typically seen in non-immune travellers, whereas chronic schistosomiasis is more frequently diagnosed in immigrants. Travellers with AS initially present with non-specific signs such... more

Download (145)

View PDF (181)

Praziquantel for the treatment of schistosomiasis during human pregnancy

Friedman, J.F. et al. (2018) CC

In 2014, an estimated 40 million women of reproductive age were infected with Schistosoma haematobium, S. japonicum and/or S. mansoni. In both 2003 and 2006, the World Health Organization (WHO) recommended that all schistosome-infected pregnant and breastfeeding women be offered treatment, with praz... more

Download (244)

View PDF (328)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (20)

View PDF (50)

WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more